Skip to main content
Clinical Trials/DRKS00013906
DRKS00013906Completed未知

Short term effects of Nasal High Flow Therapy on autonomic nervous system function in patients with pulmonary arterial hypertension.

Department für Neurologie - Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster0 sites12 target enrollmentStarted: August 8, 2018Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
12

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
N/a: Single Arm Study
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to one (—)
Sex
All

Inclusion Criteria

  • a. Age > 18 years (no age limit)
  • b. able to consent
  • c. Diagnosis of Nizza class I pumonary arterial Hypertension -PAH- according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination for PAH -where there was no treatment with combination therapy in PAH patients then the reason must be documented-

Exclusion Criteria

  • - secondary (postcapillary) pulmonary hypertension (mean pulmonary arterial hypertension > 25 mmHg; PCWP >15 mmHg)
  • - other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment
  • - severe neurological pre-existing conditions such as stroke, especially brainstem infarction
  • - intake of opioids
  • - severe psychiatric pre-existing conditions

Investigators

Sponsor
Department für Neurologie - Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster

Similar Trials

Short term effects of Nasal High Flow... | Clinical Trial